You are hereHome CategoriesJordan
Tabuk Pharmaceuticals signs license and supply agreement with Selectchemie
Source: PRNewswire , Author: Posted by BI-ME staff
Posted: Fri October 6, 2017 11:56 am

JORDAN. -- /PRNewswire/ -- Tabuk Pharmaceutical Manufacturing Company ("Tabuk"), one of the leading pharmaceutical companies in the Middle East and North Africa (MENA) region, has entered into an agreement with Selectchemie, under which Selectchemie granted Tabuk a license to register, market and sell Caspofungin Injection (systemic antifungal agent) in Saudi Arabia, the Gulf Countries, North Africa, and the rest of Middle East.

Selectchemie is one of the leading European companies, headquartered in Zurich serving the pharmaceutical and human nutrition industries since 1969 as a premier supplier of high quality ingredients.

Dr. Rana Azzam, Senior VP of Business Development said "We are excited about this major partnership collaboration with Selectchemie. Caspofungin Injection is a hard to develop and lifesaving product. This partnership will provide an opportunity for both companies to leverage their combined strength."

Selectchemie side commented "Dr. Peter Kaufmann, CEO of Selectchemie, is proud to have gained Tabuk Pharmaceutical Manufacturing Company as a licensing and marketing partner for Caspofungin in the MENA Region. With this highest quality product, manufactured in Europe, Selectchemie looks forward to a long-term partnership with Tabuk to the benefit of both companies and end-users."

 

MIDDLE EAST BUSINESS COMMENT & ANALYSIS

date:Posted: October 23, 2017
UAE. Investors betting on faster economic growth bought riskier assets while bond holders reduced their positions on worries that inflation and federal borrowing could rise.
date:Posted: October 23, 2017
UAE. Overwhelming Majority expect significant barriers; Chief AI Officer emerging to drive strategy and ROI from AI technologies.
date:Posted: October 21, 2017
INTERNATIONAL. Leadership commitment, resilience and collaboration critical to success; 40% of survey respondents cite the disruption of operations as the biggest consequence of a cyberattack, followed by the compromise of sensitive data (39%), harm to product quality (32%), and harm to human life (22%).
dhgate